Current advances in kidney cancer immunotherapy

• Main Authors: A. A. Korotaeva, N. V. Apanovich, E. A. Braga, V. B. Matveev, A. V. Karpukhin
• Format: Article
• Language: Russian
• Published: ABV-press 2020-01-01
• Series: Onkourologiâ
• Subjects: immunotherapy; kidney cancer; anti-pd-1; anti-pd-l1; anti-ctla-4; immune response checkpoint inhibitors; microrna; targeted therapy
• Online Access: https://oncourology.abvpress.ru/oncur/article/view/993
• ISSN: 1726-9776; 1996-1812

In Russia, among tumors of the genitourinary system, renal cell carcinoma takes the 2nd place after prostate cancer. In 25 % of patients at the time of diagnosis, metastases are detected. Treatment of advanced stages of renal cell carcinoma is often not effective enough. The introduction into clinical practice of modern immunotherapeutic drugs based on inhibition of immune check points has changed the prognosis of the disease for many patients with various malignant neoplasms, including kidney cancer. In this article, we described the results of recent clinical trials on the use of immunotherapy in the treatment of kidney cancer. The most effective is combination of drugs that inhibit different immune check points, and a combination of a check point inhibitor with a targeted drug. This approach is likely to be a major one in the treatment of renal cell carcinoma in the short term. Combinations of control point inhibitors with radiation therapy and immunomodulatory drugs, the role of miRNAs in the regulation of expression of immune control points, the significance and characteristics of the microbiome in connection with the success of immunotherapy for kidney cancer, gene expression profiles as biomarkers of the immune response, and other biomarkers are considered. A better understanding of the mechanisms that limit the effectiveness of immune control point inhibitors will improve future treatment.